PIQUR Therapeutics AG

PIQUR is a Swiss clinical-stage pharmaceutical company incorporated in August 2011 as a spin-off of the University of Basel, focusing on the discovery and development of innovative anti-cancer drugs based on lipid kinase (PI3K) and mTOR inhibition. PIQUR’s pipeline originates from one of the most promising research areas in oncology. Both PI3K and mTOR are clinically validated drug targets in oncology. PIQUR has a secured patent scope protecting many chemical compounds. PIQUR’s lead compound, PQR309, is a novel, balanced pan-class 1 PI3K/mTOR inhibitor formulated for oral administration. Preclinical studies demonstrated that PQR309 is a highly selective kinase inhibitor, penetrating blood-brain barrier with potent in vitro as well as in vivo antitumor activity.  A first-in-man clinical Phase 1 study was successfully completed and the maximum tolerated dose has been determined.

PIQUR Therapeutics AG
Technologiepark Basel
Hochbergerstrasse 60C
4057 Basel

Tel.: +41 61 633 29 29
Fax: +41 61 633 29 41


company website

testimonial about Technologiepark Basel

The Technology Park Basel offers the ideal and inspiring environment for start-up & early-stage companies in life sciences to thrive. PIQUR is delighted to benefit from the excellent infrastructure, services and flexible rental conditions offered.